Goldman Sachs raises target for Eli Lilly stock to USD 1,413

Published on 10/26/2026 at 17:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Earnings are due October 29, 2026. Eli Lilly stock costs EUR 1,145.40 on October 26, 2026, plus 0.07 percent versus the October 23 Xetra close.

Analyst target and earnings date

Goldman Sachs raised its Eli Lilly target from USD 1,371.00 to USD 1,413.00 on October 23, 2026.
Second-quarter 2026 revenue reached USD 22.97 billion, up 47.70 percent year over year.
Eli Lilly stock costs EUR 1,145.40 at Lang & Schwarz on October 26, 2026 at 5:00 p.m. CET, 0.07 percent above the Xetra close of October 23, 2026.
The next earnings call is scheduled for October 29, 2026.

Eli Lilly and Co., US5324571083, Illustration mit AI erstellt.

Eli Lilly and Co. (ISIN US5324571083) is heading into its October 29 earnings call with Goldman Sachs having raised its 12-month price target from USD 1,371.00 to USD 1,413.00 on October 23, 2026, as reported by TheStreet. At Lang & Schwarz, the stock was trading at EUR 1,145.40 on October 26, 2026 at 5:00 p.m. CET, up 0.07 percent versus the Xetra close of October 23, 2026 at EUR 1,144.60.

Goldman target reaches USD 1,413

The new Goldman target stands 10.40 percent above Eli Lilly's USD 1,279.88 NYSE price at 12:02 p.m. ET on October 26, 2026. The target change gives the analyst view a clear earnings-week reference point, while the euro quotation is almost unchanged against the latest Xetra close.

Revenue grew 47.70 percent

Eli Lilly reported USD 22.97 billion in second-quarter 2026 revenue, up 47.70 percent from the same quarter of 2025, according to MarketBeat. The company guides to USD 85.00 billion to USD 87.00 billion in full-year 2026 revenue, while Goldman Sachs models USD 89.80 billion, as reported by TheStreet.

Valuation meets the next date

The NYSE listing had a market capitalization of USD 1.2 trillion and a trailing price-to-earnings ratio of 42.95 on October 26, 2026. Its USD 809.63 to USD 1,321.21 52-week range places the primary-exchange price 3.13 percent below the high. The company lists its third-quarter 2026 earnings call for October 29, 2026, at 10:00 a.m. EDT on its investor site.

What does the target mean for valuation?

The answer is that expectations remain demanding. Goldman Sachs expects third-quarter revenue of USD 23.10 billion, 2.80 percent above consensus, while its adjusted earnings-per-share estimate of USD 5.63 is below the USD 7.03 consensus because of a USD 4.20 billion pretax acquired research charge, according to TheStreet. That split makes the October 29 report important for both revenue delivery and the treatment of acquisition-related costs.

Euro quote holds near the Xetra close

Eli Lilly stock was trading at EUR 1,145.40 at Lang & Schwarz on October 26, 2026 at 5:00 p.m. CET, 0.07 percent above the Xetra close of October 23, 2026 at EUR 1,144.60. The primary listing was at USD 1,279.88 on the NYSE on October 26, 2026 at 12:02 p.m. ET. The further course of trading is shown by the continuously updated real-time quote of Eli Lilly stock.